Novel studies focus Namilumab, a monoclonal antibody targeting CSF2 (Colony Stimulating Factor 2), also known as GM-CSF. This unique therapeutic approach is showing promise in treating conditions driven by https://tiffanyjzhh510823.wikiexpression.com/6594852/namilumab_a_deep_dive_into_the_csf2_antibody_medication